Compare UFPT & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UFPT | AAPG |
|---|---|---|
| Founded | 1963 | 2009 |
| Country | United States | China |
| Employees | N/A | 767 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 1996 | N/A |
| Metric | UFPT | AAPG |
|---|---|---|
| Price | $238.80 | $19.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $289.00 | $48.40 |
| AVG Volume (30 Days) | ★ 174.0K | 14.3K |
| Earning Date | 05-01-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.44 | N/A |
| EPS | ★ 2.24 | N/A |
| Revenue | ★ $602,797,000.00 | N/A |
| Revenue This Year | $8.12 | $290.34 |
| Revenue Next Year | $5.72 | N/A |
| P/E Ratio | $105.45 | ★ N/A |
| Revenue Growth | ★ 19.50 | N/A |
| 52 Week Low | $173.86 | $16.36 |
| 52 Week High | $279.49 | $48.45 |
| Indicator | UFPT | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 46.07 | 45.77 |
| Support Level | $224.12 | $16.64 |
| Resistance Level | $255.50 | $20.40 |
| Average True Range (ATR) | 10.89 | 0.54 |
| MACD | -2.61 | -0.01 |
| Stochastic Oscillator | 17.09 | 19.27 |
UFP Technologies Inc is a contract development and manufacturing organization that specializes in single-use and single-patient medical devices. The company manufactures its products by converting raw materials using laminating, molding, radio frequency, and impulse welding, and fabricating manufacturing techniques. It is an important link in the medical device supply chain and a valued outsource partner to many of the top medical device manufacturers in the world. The company's single-use and single-patient devices and components are used in a wide range of medical devices, disposable wound care products, infection prevention, minimally invasive surgery, wearables, orthopedic soft goods, and orthopedic implant packaging.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.